natgillin/translations-raw huggingface dataset:
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleeds or blood in the urine.
Krvarenje se može pojaviti u obliku krvarenja u želucu ili crijevima, modrica, hematoma (neuobičajeno krvarenje ili modrice ispod kože), krvarenja iz nosa ili krvi u mokraći.
bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion)
krvarenje nakon operacije, uključujući nastanak modrica i oticanje, istjecanje krvi ili tekućine iz kirurške rane/reza (iscjedak iz rane)
bleeding of gums
krvarenje iz desni
bleeding of the gums
krvarenje desni
bleeding of the mucous membrane that lines the inner surface of the eyelids, blurred vision, drowsiness, intolerance to light, itchy eyes, facial pain, inflamed gums,
krvarenje iz sluznice koja oblaže unutarnju površinu kapaka, zamagljen vid, omamljenost, nepodnošenje svjetla, svrbež očiju, bol lica, upaljene desni,
bleeding of the mucous membrane that lines the inner surface of the eyelids, blurred vision, drowsiness, intolerance to light, itchy eyes, facial pain, inflamed gums,
krvarenje iz sluznice koja oblaže unutarnju površinu kapaka, zamagljen vid, pospanost, nepodnošenje svjetla, svrbež očiju, bol lica, upaljene desni,
bleeding of the mucous membrane that lines the inner surface of the eyelids, itchy eyes, eye pain, blurred vision, intolerance to light,
krvarenje iz sluznice koja oblaže unutarnju površinu kapaka, svrbež očiju, bol u oku, zamagljen vid, nepodnošenje svjetla,
bleeding or bruising
krvarenje ili modrice
Bleeding or bruising after you stop treatment
Krvarenje ili modrice nakon prestanka liječenja
bleeding or bruising easily
krvarenje ili lako stvaranje modrica
bleeding or bruising in the absence of injury
krvarenje ili nastanak modrica koje nisu prouzročene ozljedama
Bleeding or bruising in the absence of injury.
Krvarenje ili nastanak modrice bez ozljede.
bleeding or bruising more easily - these may be signs of a drop in the number of blood platelets (thrombocytopaenia)
krvarenje ili lako nastajanje modrica - to mogu biti znakovi pada broja krvnih pločica (trombocitopenija)
bleeding or bruising more easily than normal (thrombocytopenia)
krvarenje i pojava modrica češće nego što je normalno (trombocitopenija)
Bleeding or bruising without a cause, including nosebleeds and bleeding from the bowels or stomach (due to effects on blood cells called ‘platelets’).
krvarenje ili nastanak modrica bez uzroka, uključujući krvarenje iz nosa i krvarenje iz crijeva ili želuca (zbog učinaka na krvne pločice koje se zovu i „trombociti“)
bleeding or haematoma
hematom
bleeding or oral bleeding
krvarenje u mišiće ili iz
bleeding or oral bleeding
u mišiću ili usnoj šupljini
bleeding or oral bleeding.
krvarenje ili krvarenje
bleeding or oral bleeding.
u zglobove, mišićno
Bleeding Outcomes
Ishodi krvarenja
bleeding problems and/or low number of platelets in your blood
tegobe s krvarenjem i/ili snižen broj krvnih pločica
bleeding problems and/or low number of platelets in your blood
tegobe s krvarenjem i/ili snižen broj krvnih pločica u krvi
Bleeding problems: Kadcyla can lower the number of platelets in your blood.
Problemi s krvarenjem: Kadcyla može sniziti broj trombocita u krvi.
bleeding requiring treatment cessation bleeding leading to re-operation
krvarenje koje zahtijeva prekid liječenja krvarenje koje vodi do ponovne operacije
Bleeding Risk Associated with Timing of Loading Dose in NSTEMI
Rizik od krvarenja povezan s vremenom primjene udarne doze kod NSTEMI
Bleeding risk may be increased in patients concomitantly treated with selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs) (see section 4.5).
Rizik od krvarenja se može povećati kod bolesnika koji se istovremeno liječe selektivnim inhibitorom ponovne pohrane serotonina (SSRI) ili selektivnim inhibitorom ponovne pohrane serotonina i noradrenalin (SNRI) (vidjeti dio 4.5).
Bleeding risk may be increased in patients concomitantly treated with selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs) (see section 4.5).
Rizik od krvarenja se može povećati kod bolesnika koji se istovremeno liječe selektivnim inhibitorom ponovne pohrane serotonina (SSRI) ili selektivnim inhibitorom ponovne pohrane serotonina i noradrenalina (SNRI) (vidjeti dio 4.5).
bleeding such as gut bleed, purple spots on body due to broken blood vessels
krvarenje poput krvarenja iz crijeva, purpurne točke po tijelu zbog pucanja krvnih žila
bleeding that is severe or that you cannot control
teško krvarenje ili krvarenje koje ne možete kontrolirati
bleeding that is severe or that you cannot control
teško krvarenje ili krvarenje koje ne možete zaustaviti,
bleeding that occurs around the eye (periorbital bleeding)
krvarenje oko oka (periorbitalno krvarenje)
Bleeding time prolonged
Produženo vrijeme krvarenja
Bleeding time prolonged, neutrophil count decreased, platelet count decreased
produljeno vrijeme krvarenja, smanjen broj neutrofila, smanjen broj trombocita
Bleeding time prolonged, neutrophil count decreased, platelet count decreased
produljeno vrijeme krvarenja, smanjeni broj neutrofila, smanjeni broj trombocita
bleeding ulcers,
čirevi koji krvare,
bleeding under the skin (ecchymosis);
potkožno krvarenje (ekhimoze);
Bleeding under the skin or around the eye, infection of bleeding sites, heavy menstrual bleeding, bleeding from the penis, ear or pre-existing skin tumours.
Krvarenje ispod kože ili oko očiju, infekcija mjesta krvarenja, teško menstruacijsko krvarenje, krvarenje iz penisa, uha ili već postojećih tumora kože.
bleeding within the brain, high blood pressure, blood clot in the lung, swelling
krvarenje u mozgu, visok krvni tlak, krvni ugrušak u plućima, oticanje
Bleeding within the skull
krvarenje unutar lubanje
Bleeding, at various sites in the body, which may be mild or serious
krvarenje u različitim dijelovima tijela, koje može biti blago ili ozbiljno
Bleeding, bruising, hardness, swelling and itching where the injection is given
krvarenje, modrice, otvrdnuće, oticanje i svrbež na mjestu primjene injekcije
Bleeding, bruising, hardness, swelling and itching where the injection is given
krvarenje, modrice, otvrdnuće, oticanje, svrbež, crvenilo i bol na mjestu primjene injekcije
Bleeding, bruising, weakness, confusion, fever, nausea, vomiting and diarrhoea, and acute kidney failure, which may be signs of a blood condition known as thrombotic microangiopathy
Krvarenje, nastanak modrica, slabost, smetenost, vrućica, mučnina, povraćanje i proljev te akutno zatajenje bubrega, što mogu biti znakovi poremećaja krvi poznatog kao trombotička mikroangiopatija
bleeding, fluid retention, swollen legs, blood clots
krvarenje, zadržavanje tekućine, oticanje nogu, krvni ugrušci
bleeding, including bleeding in the lungs in patients with non-small cell lung cancer,
krvarenje, uključujući krvarenje u plućima u bolesnika s rakom pluća nemalih stanica,
Bleeding, partial or complete blocking of blood vessels, reduced blood pressure
krvarenje, djelomično ili potpuno začepljenje krvnih žila, snižen krvni tlak
bleeding, partial or complete blocking of blood vessels, reduced blood pressure
krvarenje, djelomično ili potpuno začepljenje krvnih žila, snižen krvni tlak,
bleeding, tender or enlarged gums
krvarenje desni, osjetljive ili povećane desni
bleeding, tender or enlarged gums
krvarenje, napetost ili otok desni
Bleeding1)
krvarenje1)
Bleeding:
Krvarenje:
Bleeding: including blood in the stools.
Krvarenje: uključujući krv u stolici.
Bleeding: Very common (may affect more than 1 in 10 people) - this includes bleeding from the nose, but may also include severe bleeding in your gut and other parts of the body, which may lead to death.
Krvarenje: Vrlo često (mogu se javiti u više od 1 na 10 osoba) - uključuje krvarenje iz nosa, ali može uključivati i teško krvarenje u crijevima i drugim dijelovima tijela, koje može uzrokovati smrt.
blepharal pigmentation, hirsutism, periocular skin hyperpigmentation.
pigmentacija vjeđa, hirzutizam, hiperpigmentacija kože oko oka
blepharal pigmentation, macular oedema, periorbital and lid changes including deepening of the eyelid sulcus, dry eye
pigmentacija vjeđa, makularni edem, promjene na periorbitalnom području i vjeđama uključujući produbljenje brazde vjeđe, suho oko
blepharitis,
blefaritis,
blepharospasm, retinal haemorrhage, uveitis.
blefarospazam, retinalno krvarenje, uveitis
Blincyto acts as a ‘bridge’ to bring the T-cells and the B-cells together.
Blincyto djeluje kao „most” koji spaja T stanice i B stanice.
Blincyto can only be obtained with a prescription, and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood.
Blincyto se izdaje samo na liječnički recept te liječenje mora započeti i nadzirati liječnik koji je iskusan u liječenju raka krvi.
Blincyto contains the active substance blinatumomab.
Sadrži djelatnu tvar blinatumomab.
BLINCYTO dose calculations are based on a usual overfill volume of 265 to 275 mL sodium chloride 9 mg/mL (0.9%) solution for injection.
Izračuni doze za BLINCYTO temelje se na uobičajenom dodatnom volumenu otopine natrijeva klorida 9 mg/ml (0,9%) za injekcije od 265 do 275 ml.
BLINCYTO has been evaluated in paediatric patients with relapsed or refractory B-precursor ALL in a phase I/II dose escalation/evaluation study.
BLINCYTO je procijenjen u pedijatrijskih bolesnika s recidivirajućim ili refraktornim ALL-om prekursora B limfocita u ispitivanju eskalacije doze/evaluacijskom ispitivanju faze I/II.
Blincyto has been given ‘conditional approval’.
Za lijek Blincyto izdano je „uvjetno odobrenje”.
Blincyto has been studied in one main study in 189 patients with Ph- B-cell precursor ALL whose leukaemia had come back or had not responded to treatment.
Blincyto je ispitan u jednom glavnom ispitivanju u 189 bolesnika s recidivirajućim Philadelphia kromosom negativnim ALL-om prekursora B limfocita koji nisu odgovorili na prethodnu terapiju.
Blincyto is a cancer medicine used to treat adult patients with B-precursor acute lymphoblastic leukaemia (ALL), a type of blood cancer.
Blincyto je antikancerogeni lijek koji se koristi za liječenje odraslih bolesnika s akutnom limfoblastičnom leukemijom (ALL) prekursora B limfocita, tipom raka krvi.
Blincyto is available as a powder that is made up into a solution for infusion (drip) into a vein.
Blincyto je dostupan kao prašak koji se koristi za pripremu otopine za infuziju (drip) u venu.
BLINCYTO is compatible with polyolefin, PVC non-di-ethylhexylphthalate (non-DEHP), or ethyl vinyl acetate (EVA) infusion bags/pump cassettes.
BLINCYTO je kompatibilan s poliolefinskim, PVC (bez dietilheksilftalata (DEHP)) ili etilvinilacetat (EVA) vrećicama za infuziju/kasetama za pumpu.
BLINCYTO is indicated for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).
BLINCYTO je indiciran za liječenje odraslih osoba s recidivirajućom ili refraktornom Philadelphia kromosom negativnom akutnom limfoblastičnom leukemijom (ALL) prekursora B limfocita.
Blincyto is infused continuously during a treatment cycle of 4 weeks using a pump device.
Blincyto se ubrizgava kontinuirano tijekom terapijskog ciklusa od četiri tjedna primjenom pumpe.
Blincyto is used when the ALL has come back or has not responded to previous treatment.
Blincyto se koristi u slučajevima kada je nastupio recidiv ALL-a ili ako bolesnik nije odgovorio na prethodnu terapiju.
BLINCYTO is usually given for 2 treatment cycles.
BLINCYTO se obično daje u 2 ciklusa liječenja.
BLINCYTO may not be suitable for you: if you have ever had neurological problems, for example, shaking (or tremor), abnormal sensations, seizures, memory loss, confusion, disorientation, loss of balance, or difficulty in speaking.
BLINCYTO možda nije primjeren za Vas: ako ste ikada imali neurološke probleme, na primjer tresavicu (ili tremor), abnormalne osjete, napadaje, gubitak pamćenja, smetenost, dezorijentaciju, gubitak ravnoteže ili poteškoće u govoru.
Blincyto must not be given to breastfeeding women.
Blincyto se ne smije primjenjivati u žena koje doje.
BLINCYTO should be infused through a dedicated lumen.
BLINCYTO se treba primijeniti infuzijom kroz određeni lumen.
BLINCYTO should not be used in children and adolescents below 18 years of age.
BLINCYTO se ne smije primjenjivati u djece i adolescenata mlađih od 18 godina.
BLINCYTO solution for infusion is administered as a continuous intravenous infusion delivered at a constant flow rate using an infusion pump over a period of up to 96 hours.
BLINCYTO otopina za infuziju primjenjuje se u obliku kontinuirane intravenske infuzije pri konstantnoj brzini protoka, pomoću infuzijske pumpe, tijekom perioda u trajanju do 96 sati.
BLINCYTO treatment start date
Datum početka liječenja lijekom BLINCYTO.
BLINCYTO was evaluated in an open-label, multicentre, single-arm phase II study of 189 patients.
BLINCYTO je procijenjen u 189 bolesnika u otvorenom, multicentričnom ispitivanju faze II s jednom skupinom.
blind spot or blind area in the field of vision
lijepa točka ili slijepo područje u vidnom polju
Blinded, ranked assessments of both necro- inflammatory activity and fibrosis at baseline and week 48, demonstrated that patients treated with 10 mg adefovir dipivoxil had improved necro-inflammatory and fibrosis scores relative to placebo- treated patients.
Slijepa, rangirana procjena i nekro-upalne aktivnosti i fibroze na početku te u 48. tjednu pokazala je da su pacijenti liječeni s 10 mg adefovirdipivoksila imali poboljšane rezultate nekro-upalnih promjena i fibroze u odnosu na pacijente koji su primali placebo.
blindness
ljepoća
blindness
sljepoća
Blindness and other visual disturbances
Sljepoća ili drugi poremećaji vida
Blindness transient, retinal exudates, visual impairment eye irritation, eye pain, eye pruritis
prolazna sljepoća, eksudati u mrežnici, poremećaj vida, iritacija oka, bol u oku, svrbež oka
Blindness transient, retinal exudates, visual impairment, eye irritation, eye pain, eye pruritis
prolazna sljepoća, eksudati u mrežnici, poremećaj vida, iritacija oka, bol u oku, svrbež oka
Blindness, deafness
ljepoća, gluhoća
Blink a few times so that the medicine covers your eye.
Trepnite nekoliko puta kao bi lijek prekrio oko.
Blink your eye(s) a few times.
Trepnite okom/očima nekoliko puta.
Blinking display number
Trepereće prikazan broj
Blinking red light for 15 seconds
Crveno svjetlo treperi 15 sekundi
BLISS-52 was conducted in South America, Eastern Europe, Asia, and Australia.
Studija BLISS-52 je bila provedena u Južnoj Americi, istočnoj Europi, Aziji i Australiji.
BLISS-76 and BLISS-52
BLISS-76 i BLISS-52 skupno
BLISS-76 Study only
Samo BLISS-76 studija
BLISS-76 was conducted primarily in North America and Western Europe.
Studija BLISS-76 bila je primarno provođena u Sjevernoj Americi i zapadnoj Europi.
blister
Blister (PVC/PVDC/al)
blister
blisteru
blister
EU/1/03/256/012
blister
mjehur
blister
OPA/Al/PVC-Al
blister
OPA/Al/PVC-Al blister
BLISTER
{OSOBINE/TIP}
BLISTER (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet)
BLISTER (14x1, 28x1, 30 x1, 50x1, 90 x1 ili 100 x1 filmom obloženih tableta)
BLISTER (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablets)
(BLISTER 14 x1, 28 x1,30x1, 50x1, 84 x1, 90x1 ili 100x1 filmom obloženih tableta)
BLISTER (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablets)
BLISTER (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 filmom obloženih tableta)
BLISTER (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablets)
BLISTER(14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 filmom obloženih tableta)
BLISTER (28, 28x1, 30, 30x1, 50, 50x1, 56, 56x1, 84, 84x1, 90, 90x1, 100, 100x1 film-coated
BLISTER (28, 28x1, 30, 30x1, 50, 50x1, 56, 56x1, 84, 84x1, 90 90x1, 100, 100x1 filmom
BLISTER (28, 28x1, 30, 30x1, 50, 50x1, 56, 56x1, 84, 84x1, 90, 90x1, 100, 100x1 film-coated
BLISTER(28, 28x1,/30, 30x1, 50, 50x1, 56, 56x1, 84, 84x1, 90 90x1, 100 100x1 filmom obloženih
BLISTER (28x1 film-coated tablets)
(BLISTER 28x1 filmom obloženih tableta)
BLISTER (28x1 film-coated tablets-calendar pack)
(BLISTER 28x1 filmom obloženih tableta-kalendarsko pakiranje)
BLISTER (7, 14, 28, 30, 50, 56, 84, 90, 100, 50x1 film-coated tablets)
BLISTER (7, 14, 28, 30, 50, 56, 84, 90, 100, 50x1, filmom obloženih tableta)
Blister (Aclar/polyethylene/PVC) Bottle (polyethylene
Bočica (polietilen
blister (Aclar/PVC/ alu)
Blister (Aclar/PVC/ Al)
blister (Aclar/PVC/alu)
Blister (Aclar/PVC/ Al)
blister (Aclar/PVC/alu) blister (Aclar/PVC/alu) blister (Aclar/PVC/alu)
Blister (Aclar/PVC/Al) Blister (Aclar/PVC/Al) Blister (Aclar/PVC/Al)
BLISTER (ALL BLISTER PACKS):
BLISTER (SVA BLISTER PAKOVANJA):
blister (alu)
blister (Al)
blister (alu)
Blister (aluminij)
Blister (alu)/alu
Perorální podání
blister (Alu/Alu foil)
Blister (Al/Al folija)
blister (Alu/Alu)
Alu/Alu blister
blister (alu/alu)
blister (Al/Al)
blister (Alu/Alu)
blister (Al/Al) blister (Al/Al)
blister (alu/alu)
blister (alu-alu) blister (alu-alu)
blister (Alu/Alu)
blister (aluminij/aluminij)
blister (alu/alu)
blister(alu/alu)
Blister (Alu/Alu)
blistere aluminij/aluminij
blister (alu/alu)
EU/1/08/475/024
Blister (alu/alu)
Pakovanje
Blister (alu/alu)
Perorální podání
blister (alu/alu) (peelable)
blister (alu/alu) (s odvojivim slojem)
blister (alu/polyamide
blister (alu/poliamid/PVC)
blister (alu/PVC)
blister (Al/PVC)
blister (alu/PVC) in wallet card
blister (Al/PVC) u kartonskom ovitku u obliku novčanika
blister (Alu/PVC/PE/PVDC)
blister (Al/PVC/PE/PVDC)
blister (Alu/PVC/PVDC)
blister (Al/PVC/PVDC)
Blister (alualu)
Perorální podání
blister (Aluminium/aluminium)
Blister (aluminij/aluminij)
Blister (Blister foil for 200 mg film-coated tablets (all blister packs))
Blister (Blister folija za 200 mg filmom obložene tablete (sva blister pakovanja))
Blister (Blister foil for 50 mg film-coated tablets (all blister packs))
Blister (Blister folija za 50 mg filmom obložene tablete (sva blister pakovanja))
BLISTER (Boxes of 7, 14, 28, 30, 30x1, 50, 50x1, 56, 84, 90 and 100)
BLISTER (kutije s 7, 14, 28, 30, 30x1, 50, 50x1, 56, 84, 90 i 100 tableta)
BLISTER (CALENDAR PACK)
BLISTER (KALENDARSKO PAKOVANJE)
Blister (OPA/Al/PE foil with desiccant//Al foil):
Blister (OPA/Al/PE folija sa sredstvom za sušenje//Al folija):
Blister (OPA/Al/PVC foil//Al foil):
Blister (OPA/Al/PVC folija//Al folija):
Blister (OPA/Alu /PVC-Alu)
Blister (OPA/Alu /PVC- Alu)
blister (OPA/Alu/DES/PE-Alu)
Blister (OPA/Al/desikant/PE- Al folija)
Blister (OPA/Alu/desiccant/PE-Alu foil): 21 prolonged-release tablets (3 blisters of 7 tablets):
Blister (OPA/Al/desikant/PE-Al folija): 21 tableta s produljenim oslobađanjem (3 blistera sa po 7 tableta):
blister (OPA/Alu/PE+DES/Alu)
Blister (OPA/Al/PE+DES/Al)
blister (OPA/Alu/PVC - Alu)
blister (OPA/Al/PVC Al)
blister (OPA/alu/PVC)
blister (OPA/alu/PVC
Blister (OPA/Alu/PVC, Alu-foil): 14, 28, 35, 56 or 70 tablets in a box.
Blister (OPA/Al/PVC, Al-folija): 14, 28, 35, 56 ili 70 tableta u kutiji.
Blister (OPA/Alu/PVC, Alu-foil): 7, 14, 28, 35, 56 or 70 tablets in a box.
Blister (OPA/Al/PVC, Al-folija): 7, 14, 28, 35, 56 ili 70 tableta u kutiji.
blister (OPA/alu/PVC//alu)
blister OPA/Al/PVC//Al
blister (oPA/alu/PVC/alu)
(oPA/alu/PVC/alu) blister
blister (OPA/Alu/PVC/Alu)
Blister (OPA/Al/PVC/Al)
blister (OPA/Alu/PVC/Alu)
OPA/Al/PVC/Al blister
blister (oPA/alu/pvc/polyester/ alu)
blister (oPA/alu/ PVC/poliester/alu)
blister (PA-
Blister (PA- aluminij/PVC/aluminij)
blister (PA/Alu/PVC –
blister (PA/Al/PVC
blister (PA/Alu/PVC –
blister (PA/Al/PVC – Al)
blister (PA/Alu/PVC)
blister (PA/Al/PVC)
Blister (Particulars printed directly onto the wallet card with the blank blister sealed inside)
Blister (Podaci otisnuti izravno na kartonski ovitak oblika novčanika, s blisterom bez ikakvih podataka zalijepljenim unutar ovitka.)
blister (PCTFE/PVC/alu)
blister (PCTFE/PVC/Al)
BLISTER (pipette label)
BLISTER (etiketa na pipetama)
BLISTER (pipette label)
BLISTER (naljepnica na pipetama )
Blister (Polyamide/ Alu/PVC)/Alu)
Blisteri Poliamid/alu
Blister (Polyamide/alu/PVC/alu)
Blister (poliamid/alu/PVC/alu)
blister (PP/alu)
blister (PP/Al)
blister (PP/alu)
blister (PP/aluminij)
blister (PVC/ PCTFE/ Alu)
blister(PVC/ PCTFE/Alu)
blister (PVC/aclar/Alu) blister (PVC/aclar/Alu) vial (glass)
blister (PVC/aclar/Al) blister (PVC/aclar/Al)
Blister (PVC/alu)
Blister
blister (PVC/Alu)
Blister (PVC/alu))
blister (PVC/alu)
Blister (PVC/aluminij)
blister (PVC/Alu)
blister (PVC/aluminijski)
blister (PVC/alu) in a card
blister (PVC/alu) kartica
blister (PVC/alu) in a card
blister (PVC/alu) u kartonskom
blister (PVC/alu) in a carton
blister (PVC/alu) u kutiji
blister (PVC/alu) non perforated
Blister (PVC/alu)
blister (PVC/OPA/alu)
blister (PVC/OPA/Al)
blister (PVC/PCTFE, alu)
blister (PVC/OPA/Al)
blister (PVC/PCTFE, alu)
blister (PVC/PCTFE, Al)
Blister (PVC/PCTFE/Alu)
Blister (PVC/PCTFE/Al)
Blister (PVC/PCTFE/Alu)
Blister (PVC/PCTFE/Au)
blister (PVC/PCTFE/Alu)
PVC/PCTFE/Al blister
blister (PVC/PE/aclar/alu)
Blister (PVC/PE/aklar/alu)
Blister (PVC/PE/PCTFE/Alu)
Blister (PVC/PE/PCTFE/Al)
blister (PVC/PE/PVDC/alu)
(PVC/PE/PVDC/Al)
blister (PVC/PE/PVDC/alu)
blister (PVC/PE/PVDC- aluminijski)
blister (PVC/PE/PVDC/alu)
blister (PVC/PE/PVDC/Al)
blister (PVC/PE/PVDC/Alu)
blister (PVDC/Al)
blister (PVC/PE/PVDC/alu), calendar
blister (PVC/PE/PVDC/Al), kalendarski
blister (PVC/PVDC-Alu)
blister (PVC/PVDC/Alu)
blister (PVC/PVDC-Alu); wallet
blister (PVC/PVDC/Alu); preklopni
blister (PVC/PVDC-Alu- Alu); carton
blister (PVC/PVDC/Alu); kutija
blister (PVC/PVDC/alu)
(oPA/alu/PVC/alu) blister
blister (PVC/PVDC/alu)
(PVC/PVDC/alu) blister
Blister (PVC/PVdC/Alu)
Blister (PVC/PVdC /Al)
blister (PVC/PVdC/Alu)
blister (PVC/PVdC- Aluminij)
blister (PVC/PVDC/Alu)
blister (PVC/PVDC/Al)
blister (PVC/PVDC/alu)
PVC/PVDC/Al
blister (PVC/PVDC/Alu)
PVC/PVDC/Alu blister
blister (PVC/PVDC/Alu) blister (PVC/PVDC/Alu) blister (PVC/PVDC/Alu) blister (PVC/PVDC/Alu) blister (PVC/PVDC/Alu) blister
(PVC/PVDC/Alu) blister (PVC/PVDC/Alu) blister (PVC/PVDC/Alu) blister (PVC/PVDC/Alu) blister (PVC/PVDC/Alu) blister
Blister - 10 mg tablets, 40 mg tablets and 80 mg tablets
Blister – tablete od 10 mg, tablete od 40 mg i tablete od 80 mg
BLISTER - PACKS OF 42, 84, 90, 294 FILM-COATED TABLETS
BLISTER - PAKIRANJA S 42, 84, 90, 294 FILMOM OBLOŽENIH TABLETA
Blister - Pramipexole Teva 0.088 mg Tablets
Blister - Pramipeksol Teva 0,088 mg tablete
BLISTER - unit dose
BLISTER – djeljiv na jedinične doze
BLISTER / 14, 28 and 84 tablets
BLISTER / 14, 28 i 84 tablete
BLISTER / 30, 30x1, 50x1, 90x1 and 100x1 tablets
BLISTER / 30, 30x1, 50x1, 90x1 i 100x1 tableta
BLISTER / 30x1, 50x1, 90x1 and 100x1 tablets
BLISTER / 30, 30x1, 50x1, 90x1 i 100x1 tableta
BLISTER / 30x1, 50x1, 90x1 and 100x1 tablets
BLISTER / 30x1, 50x1, 90x1 i 100x1 tableta
BLISTER / Tablets
BLISTER/Tableta
BLISTER / WALLET
BLISTER / OVITAK
BLISTER 2.5 mg (Symbol)
BLISTER 2,5 mg (simbol)
Blister 2.5 mg 3 years.
Blister 2,5 mg 3 godine.
BLISTER 4x1, 10x1, 30x1 or 100x1 tablets
BLISTER 4x1, 10x1, 30x1 ili 100x1 tableta
BLISTER Advagraf 0.5 mg prolonged-release hard capsules
BLISTER Advagraf 0,5 mg tvrde kapsule s produljenim oslobađanjem
BLISTER Advagraf 1 mg prolonged-release hard capsules
BLISTER Advagraf 1 mg tvrde kapsule s produljenim oslobađanjem
BLISTER Advagraf 3 mg prolonged-release hard capsules
BLISTER Advagraf 3 mg tvrde kapsule s produljenim oslobađanjem
BLISTER Advagraf 5 mg prolonged-release hard capsules
BLISTER Advagraf 5 mg tvrde kapsule s produljenim oslobađanjem
Blister and bottle: 3 years
Blister i boca: 3 godine
Blister backing: vinyl heat seal coating /aluminium foil/polyester film/printable paper Not all pack sizes may be marketed.
Podloga blistera: vinilna plastična obloga/aluminijska folija/poliesterska folija/papir za tiskanje Ne moraju sve veličine pakovanja biti u prometu.
BLISTER BLISTER (CALENDAR)
BLISTER BLISTER (KALENDAR)
Blister boxes contain 14, 28, or 84 tablets.
Kutije s blisterima sadrže 14, 28 ili 84 tablete.
BLISTER CARD 140 mg dose
BLISTER KARTICA, doza od 140 mg
BLISTER CARD OF 28 DAY PACK, 100 mg dose (WITHOUT BLUE BOX)
BLISTER KARTICA ZA 28 DANA PAKIRANJE, doza od 100 mg (BEZ PLAVOG OKVIRA)